REAL-WORLD CORTICOSTEROID BURDEN REDUCTION WITH SUBCUTANEOUS IMMUNOGLOBULIN IGPRO20 IN CIDP
Author(s)
Batyrkhan Kuatov, MA1, Shicheng Weng, MSc2, Laurence Undreiner, MSc3, Aisara Chansakul, MPH4, Elizabeth Dabrowski, MS4, Ann Madsen, PhD4.
1Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 2CSL Behring, Waltham, MA, USA, 3CSL Behring, Paris, France, 4Datavant, Phoenix, AZ, USA.
1Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 2CSL Behring, Waltham, MA, USA, 3CSL Behring, Paris, France, 4Datavant, Phoenix, AZ, USA.
OBJECTIVES: Chronic inflammatory demyelinating polyneuropathy (CIDP) is commonly managed with long-term immunomodulatory therapy, with corticosteroids widely used despite their associated adverse effects. Real-world evidence on corticosteroids following initiation of immunomodulatory subcutaneous immunoglobulin (IgPro20) remains limited. This study describes corticosteroid use before and after IgPro20 initiation in patients with CIDP in the US.
METHODS: This retrospective cohort study used Optum’s de-identified Clinformatics® Data Mart Database (study period: January 2014 - June 2025). Patients with CIDP who initiated IgPro20 (index date) and had ≥180 days of continuous enrollment pre- and post-index were included. Follow-up was censored at the earlier of IgPro20 discontinuation (plus a 7-day grace period) or 180 days post-index. Corticosteroid utilization (oral/intravenous claims, use, days covered, dose, frequency) was assessed over 180-day pre- and post-initiation periods using descriptive analyses.
RESULTS: The study cohort included 210 adults with CIDP who initiated IgPro20 between June 2018 and January 2025. Median age was 61 years; 53.3% of patients were male. The proportion of patients with ≥1 corticosteroid claim decreased from 38.1% pre-initiation to 29.5% post-initiation, and overall corticosteroid event rates declined from 2.66 to 1.58 per 1000 person-years. Oral corticosteroid use decreased from 27.1% to 21.4%, and mean days covered among users declined from 46.4 to 32.5 days. Intravenous corticosteroid claims decreased from 21.9% to 15.7%. The proportion of patients with no corticosteroid claims increased from 61.9% to 70.5%, while frequent corticosteroid use (≥4 claims) decreased from 12.4% to 3.3%. Findings were directionally consistent in a sensitivity analysis that extended follow-up to 365 days post-index.
CONCLUSIONS: IgPro20 initiation was followed by reduced corticosteroid burden across multiple measures, including prevalence of use, exposure, and frequency. These findings suggest that IgPro20 initiation reduces the documented burden of corticosteroids in management of patients with CIDP; the relative impact on corticosteroid-related toxicities should be confirmed in future studies.
METHODS: This retrospective cohort study used Optum’s de-identified Clinformatics® Data Mart Database (study period: January 2014 - June 2025). Patients with CIDP who initiated IgPro20 (index date) and had ≥180 days of continuous enrollment pre- and post-index were included. Follow-up was censored at the earlier of IgPro20 discontinuation (plus a 7-day grace period) or 180 days post-index. Corticosteroid utilization (oral/intravenous claims, use, days covered, dose, frequency) was assessed over 180-day pre- and post-initiation periods using descriptive analyses.
RESULTS: The study cohort included 210 adults with CIDP who initiated IgPro20 between June 2018 and January 2025. Median age was 61 years; 53.3% of patients were male. The proportion of patients with ≥1 corticosteroid claim decreased from 38.1% pre-initiation to 29.5% post-initiation, and overall corticosteroid event rates declined from 2.66 to 1.58 per 1000 person-years. Oral corticosteroid use decreased from 27.1% to 21.4%, and mean days covered among users declined from 46.4 to 32.5 days. Intravenous corticosteroid claims decreased from 21.9% to 15.7%. The proportion of patients with no corticosteroid claims increased from 61.9% to 70.5%, while frequent corticosteroid use (≥4 claims) decreased from 12.4% to 3.3%. Findings were directionally consistent in a sensitivity analysis that extended follow-up to 365 days post-index.
CONCLUSIONS: IgPro20 initiation was followed by reduced corticosteroid burden across multiple measures, including prevalence of use, exposure, and frequency. These findings suggest that IgPro20 initiation reduces the documented burden of corticosteroids in management of patients with CIDP; the relative impact on corticosteroid-related toxicities should be confirmed in future studies.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HSD68
Topic
Health Service Delivery & Process of Care, Study Approaches
Disease
Rare & Orphan Diseases